TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00353106

Intervention type: BEHAVIORAL
Intervention: Interview
Description: 30-minute interviews of participating patients and their caregiver(s).

Intervention type: BEHAVIORAL
Intervention: Interview
Description: 30-minute interviews of participating patients and their caregiver(s).
Study: NCT05231434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic activity
Description: aerobic activity
Study: NCT01068548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reminder
Description: computer based reminder to change patients from IV to oral antibiotics based on evidence based clinical practice guidelines
Study: NCT04109092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7766
Description: E7766, solution, intravesically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7766
Description: E7766, solution, intravesically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7766
Description: E7766, solution, intravesically.
Study: NCT03213821

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: protein intake
Description: For each participant, weighed food records of 3 consecutive days will be analyzed for estimation of calorie and macronutrient intake and dietary preferences. To make sure good compliance, diets will be developed regarding patient's dietary habits and preferences individually. High calorie (30-35 kcal/kg Ideal body weight) diets including 6-8 small meals will be formulated. Intervention group will receive high protein diet as recommended to preserve muscle mass (1.2-1.5 g/kg IBW). Comparison group will receive protein based on GFR to preserve renal function. For older adults (\>65 years) protein content of diet will be as recommended by the international study group to review dietary protein needs with aging (PROT-AGE). In subjects with lower intake of protein, carbohydrate will be substituted. Both group will receive low fat diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: protein intake
Description: For each participant, weighed food records of 3 consecutive days will be analyzed for estimation of calorie and macronutrient intake and dietary preferences. To make sure good compliance, diets will be developed regarding patient's dietary habits and preferences individually. High calorie (30-35 kcal/kg Ideal body weight) diets including 6-8 small meals will be formulated. Intervention group will receive high protein diet as recommended to preserve muscle mass (1.2-1.5 g/kg IBW). Comparison group will receive protein based on GFR to preserve renal function. For older adults (\>65 years) protein content of diet will be as recommended by the international study group to review dietary protein needs with aging (PROT-AGE). In subjects with lower intake of protein, carbohydrate will be substituted. Both group will receive low fat diet.
Study: NCT02589782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Study: NCT02354729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral Economics
Description: Use financial incentives to promote epinephrine-carrying.
Study: NCT00353106

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires that will take approximately 5 minutes to complete.

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires that will take approximately 5 minutes to complete.

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires that will take approximately 5 minutes to complete.
Study: NCT01764399

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care4U
Study: NCT02166710

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adductor canal femoral nerve block
Description: A 18 Gauge Tuohy needle will be inserted and its position will be confirmed using ultrasound guidance. Once the adequacy of the position is confirmed, the anesthesiologist will administer 15 mL of bupivacaine 0.25% with epinephrine in divided doses and examine the quality of its spread. A 20 Gauge polyamide catheter will be inserted at 2 cm in the space. The needle will then be withdrawn and the catheter will be fixed in place. Three mL of the same mixture of local anesthetics will be administered through the catheter and the anesthesiologist will observe the quality of its distribution. Bupivacaine 0.125% will be administered through the catheter using an infusion pump for 48 hours. Knee extensor muscle strength, pain and side-effects will be assessed at different time-points.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Simulated nerve blockade
Description: The insertion of the Tuohy needle and the injection of 15 mL of bupivacaine 0.25% with epinephrine will be simulated. The insertion of the polyamide catheter, the withdrawal of the needle and the injection of local anesthetics through the catheter will also be simulated. The infusion of bupivacaine 0.125% will also be simulated for 48 hours. Knee extensor muscle strength, pain and side-effects will be assessed at different time-points.
Study: NCT02589782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.
Study: NCT03697668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: triple combination for the treatment of malaria

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine
Description: standard malaria treatment
Study: NCT01865279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Ascending single doses - 5 dose levels. Escalation to next dose level will be performed following evaluation of safety data.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Ascending single doses - 5 dose levels

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin degludec
Description: A single dose corresponding to that of isophane human insulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isophane human insulin
Description: A single dose of 0.4 IU/kg is administered to subjects with type 1 diabetes while a single dose of 0.6 IU/kg is administered to subjects with type 2 diabetes
Study: NCT01056809

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy and surgery
Description: Treatment not specified but in accordance with national guidelines

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy and surgery
Description: Treatment not specified but in accordance with national guidelines
Study: NCT02902510

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic yoga for people with Parkinson's Disease
Description: Held for 8 weeks, individuals participated in therapeutic yoga 60 minutes 2x/week.
Study: NCT04156568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INH、RFT
Description: 6INH 10mg/kg 3INH+RFT 15mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INH、RFT
Description: 6INH 10mg/kg 3INH+RFT 15mg/kg
Study: NCT01206179

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cell injection
Description: Injection of mesenchymal cells in fractured zone
Study: NCT04553432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amniotic membrane Omnigen[TM]
Description: 17mm circular disk of processed amniotic tissue donated by mother after birth with a 6mm laser cut aperture to allow unimpeded vision https://www.nu-vision.co.uk/omnigen

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bandage soft Contact Lens OmniLenz[R]
Description: 18mm soft silicone-hydrogel contact lens https://www.nu-vision.co.uk/omnilenz

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bandage soft Contact Lens OmniLenz[R]
Description: 18mm soft silicone-hydrogel contact lens https://www.nu-vision.co.uk/omnilenz
Study: NCT02443142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen 800 mg orally three times per day for two days for study subjects who are randomized to the ibuprofen arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen 1000 mg orrally three times per day for two days for subjects who are randomized to the acetaminophen arm.
Study: NCT00783445

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-Based Exercise Program (C-FIT)
Description: Participants will do 1 hour of exercise two to three times each week in a community setting for 1 year, while being supervised by a personal coach.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Help Exercise Program (HOME)
Description: After a fitness evaluation, participants will be given an exercise prescription and recommendations for home-based, self-mediated progressive exercise. Participants will be expected to do 1 hour of exercise two to three times each week for 1 year.
Study: NCT01630512

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Description: The intervention consists of 8 weekly individual sessions of MBCT. Each session will be administered individually and will last 45 to 60 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: The intervention consists of 8 weekly individual sessions of CBT. Each session will be administered individually and will last 45 to 60 minutes.
Study: NCT03167879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: safer conception counseling
Description: Multi-component counseling to help HIV-affected couples to make an informed decision about childbearing, and to provide counseling to use contraception or safer conception methods, depending on whether the couples chooses to seek or prevent pregnancy after initial consultation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: safer conception counseling
Description: Multi-component counseling to help HIV-affected couples to make an informed decision about childbearing, and to provide counseling to use contraception or safer conception methods, depending on whether the couples chooses to seek or prevent pregnancy after initial consultation.
Study: NCT02229942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Induction with two infusions two weeks apart, rituximab 500 mg/m2 (max 1000 mg).~Maintenance with rituximab infusions (500 mg fixed dose) at 3, 6, 9 and 12 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline (NaCl 0,9%) added human albumin (Flexbumin) 0,4 mg/ml, two infusions two weeks apart. Maintenance infusions after 3,6, 9 and 12 months.
Study: NCT02417688

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cu[64]-25%-CANF-Comb PET-MR
Description: Single IV injection of a novel radiopharmaceutical for diagnostic imaging of atherosclerosis by PET-MR
Study: NCT02859051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Humanoid Robot MEDi
Description: Humanoid robot programmed with cognitive-behavioral interventions such as role modeling, teaching coping strategies, positive reinforcement, parent encouragement
Study: NCT01650207

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: All participants were received regular rehabilitation program, and received different interventions.~treatment frequency: 20 minutes per session, once daily, 5 times a week for 2 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TENS

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Study: NCT03849885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide gel
Description: Skin prep with Chlorohexidine wipes and BPO.
Study: NCT02120950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: Eylea is administered as an intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: Eylea is administered as an intravitreal injection
Study: NCT00182325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: personalized web prenatal information
Study: NCT01147757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil
Description: During surgery, 3 different dose of remifentanil or placebo was infused.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil
Description: During surgery, 3 different dose of remifentanil or placebo was infused.
Study: NCT02120950

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visudyne
Description: Photodynamic therapy is a combined therapy of drug (Visudyne) applied to reinforce the action of a device (laser)
Study: NCT01147757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil
Description: During surgery, 3 different dose of remifentanil or placebo was infused.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: remifentanil
Description: During surgery, 3 different dose of remifentanil or placebo was infused.
Study: NCT03527888

Intervention type: DRUG
Group type: OTHER
Intervention: Anlotinib
Description: Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
Study: NCT01729793

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Digestive Enzyme #2
Description: Contains dietary supplement proteases, lipases and carbohydrases

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule containing microcrystalline cellulose
Study: NCT04565873

Intervention type: DIAGNOSTIC_TEST
Intervention: TSH
Description: retrospective TSH level

Intervention type: DIAGNOSTIC_TEST
Intervention: TSH
Description: retrospective TSH level
Study: NCT00182325

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: general web prenatal information
Study: NCT04258176

Intervention type: OTHER
Intervention: Multidisciplinary outpatient pathway
Description: Coordinators, assigned to improve the care flow, review and align the patient's appointments and tests in agreement with the patient's wishes. Outpatient consultations are arranged to take place the same day and schedules for care providers are coordinated. The patients' attendance in outpatient clinics are planned sequentially where the delivering specialty writes a summary to the subsequent specialty. Afterwards, the involved physicians and nurses attend an interdisciplinary conference, resulting in a joint treatment plan, with feedback and notice of modifications, which is delivered to the patient and general practice.
Study: NCT03240783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone OR Dexamethasone Injectable
Description: Procedural agents. The steroid and local anaesthetic preparation will be standardized to replicate current radiology interventional practices that use either particulate or non-particulate steroids. Betamethasone Sodium Phosphate/Acetate 5.7 mg/ml Injectable is a particulate corticosteroid and is used with the local anaesthetic bupivacaine 0.5% (1ml). Dexamethasone 4mg (1ml) is a non-particulate corticosteroid and is used with the local anaesthetic lignocaine 1% (1ml).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline Flush, 0.9% Injectable Solution
Description: Procedural agents. The local anaesthetic preparation used with the Normal Saline Flush, 0.9% Injectable Solution, will be standardized to replicate current radiology interventional practices: either local anaesthetic bupivacaine 0.5% (1ml) or local anaesthetic lignocaine 1% (1ml).
Study: NCT01892631

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text message influenza vaccination reminder
Description: Practices in the text messaging intervention arm will be asked to send a text message to patients under 65 at risk of influenza.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Practices in the standard care arm will be asked to proceed with their seasonal influenza campaign as planned.
Study: NCT04390581

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juvéderm® VOLIFT with Lidocaine
Description: Consists of one injection of Juvéderm® VOLIFT with Lidocaine to both hands no more than 6ml for both hands total on Day 1. Optional on Day 30.
Study: NCT03329690

Intervention type: DRUG
Group type: OTHER
Intervention: DS-8201a
Description: DS-8201a is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration.

Intervention type: DRUG
Group type: OTHER
Intervention: DS-8201a
Description: DS-8201a is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8201a
Description: DS-8201a is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician's Choice
Description: Either:~Irinotecan monotherapy (Starting dosage and usage is 150 mg/m2 biweekly, with dose reduction permitted)~Paclitaxel monotherapy (Starting dosage and usage is 80 mg/m2 weekly, with dose reduction permitted)
Study: NCT00951093

Intervention type: PROCEDURE
Intervention: Gastric bypass
Description: Open Silastic® ring Roux-en Y gastric bypass was performed through an upper midline incision. A gastric pouch was created by dividing the stomach with a 10-cm stapler from the lesser curvature (7 cm vertically from the cardia) to 1 cm to the left of the Hiss angle. The estimated volume of the gastric pouch was 20 to 30 ml that was banded with a 6.5 cm long Silastic® ring. A gastrojejunal anastomosis was performed with two-layers hand sewn absorbable suture over a 1.2 cm bougie distal to the ring, keeping an alimentary limb with 100 cm in length, and a biliopancreatic limb ranging 60 and 80 cm.
Study: NCT04773444

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eccentric cycling training
Description: 1. Performed exercise training 5 days a week for 6 weeks on an eccentric ergometer.~2. Each training session: 3 min at 30% of maximal workload (Wmax) for warmed up and cold down and 30 min the main training phase.~3. Intensity: Firstly, set at 45% Wmax, and progressively increased 5% per week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concentric cycling training
Description: 1. Performed exercise training 5 days a week for 6 weeks on an eccentric ergometer.~2. Each training session: 3 min at 30% of maximal workload (Wmax) for warmed up and cold down and 30 min the main training phase.~3. Intensity: Firstly, set at 45% Wmax, and progressively increased 5% per week
Study: NCT02746562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Freeze all
Description: Freezing of all blastocyst stage embryos with thawing and transfer in a subsequent natural cycle
Study: NCT01909908

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECM
Description: ECM in saline applied to wound

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood Products
Description: Autologous blood product applied to wound, with saline cleanse on alternating weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECM in Blood Products
Description: Alternating treatments of ECM in saline and ECM in autologous blood products, applied to wound
Study: NCT02857777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Subjects will self-administer intranasal esketamine as per the treatment regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine
Description: Subjects will self-administer intranasal esketamine as per the treatment regimen.
Study: NCT03412084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stand up and move more
Description: 4 week behavioral intervention involving the development and implementation of action plans
Study: NCT03610932

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Taken as 3 500mg capsules.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Taken as 3 500mg capsules.
Study: NCT00885066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study: NCT03045965

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Salpingectomy
Description: The intervention is a routine salpingectomy, performed laparoscopically, through laparotomy or vaginally.
Study: NCT03869450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Volyme
Description: Hyaluronic based filler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Defyne
Description: Hyaluronic based filler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Lyft Lidocaine
Description: Hyaluronic based filler
Study: NCT03823053

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Based Traditional Scoliosis Exercise
Description: Program will include posture exercises, strengthening exercises of interscapular muscle and limb, diaphragmatic breathing exercises and stretching exercises for lumbar extensor, hip flexor, hamstring, pectoral muscles. Exercises will be applied 1 sets of 10 repetitions and once a day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Based Traditional Scoliosis Exercise
Description: Program will include posture exercises, strengthening exercises of interscapular muscle and limb, diaphragmatic breathing exercises and stretching exercises for lumbar extensor, hip flexor, hamstring, pectoral muscles. Exercises will be applied 1 sets of 10 repetitions and once a day.
Study: NCT01394406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: ketamine 3 mg/kg mixed to intravenous patient controlled analgesia device (fentanyl 20 mcg/kg. total volume 180 ml, basal infusion 2 ml, bolus 2ml, lock-out 15 min)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: equal volume of normal saline mixed to intravenous patient controlled analgesia device
Study: NCT03672526

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: measure of injection pressure by compuflo
Description: injection pressure mesured by Compuflo